Literature DB >> 27896592

Why Have Clinical Trials of Antioxidants to Prevent Neurodegeneration Failed? - A Cellular Investigation of Novel Phenothiazine-Type Antioxidants Reveals Competing Objectives for Pharmaceutical Neuroprotection.

Maike J Ohlow1,2, Selina Sohre3, Matthias Granold3, Mathias Schreckenberger4, Bernd Moosmann5.   

Abstract

PURPOSE: Only a fraction of the currently established low-molecular weight antioxidants exhibit cytoprotective activity in living cells, which is considered a prerequisite for their potential clinical usefulness in Parkinson's disease or stroke. Post hoc structure-activity relationship analyses have predicted that increased lipophilicity and enhanced radical stabilization could contribute to such cytoprotective activity.
METHODS: We have synthesized a series of novel phenothiazine-type antioxidants exhibiting systematic variation in their lipophilicity and radical stabilization. Phenothiazine was chosen as lead structure for its superior activity at baseline. The novel compounds were evaluated for their neuroprotective potency in cell culture, and for their primary molecular targets.
RESULTS: Lipophilicity was associated with enhanced cytoprotective activity, but only to a certain threshold (logP ≈ 7). Benzannulation likewise produced improved cytoprotectants that exhibited very low EC50 values of ~8 nM in cultivated neuronal cells. Inhibition of global protein oxidation was the best molecular predictor of cytoprotective activity, followed by the inhibition of membrane protein autolysis. In contrast, the inhibition of lipid peroxidation in isolated brain lipids and the suppression of intracellular oxidant accumulation were poor predictors of cytoprotective activity, primarily as they misjudged the cellular advantage of high lipophilicity.
CONCLUSIONS: Lipophilicity, radical stabilization and molecular weight appear to form an uneasy triangle, in which a slightly faulty selection may readily abolish neuroprotective activity.

Entities:  

Keywords:  neuroprotection; oxidative stress; phenothiazine; protein oxidation; structure-activity relationship

Mesh:

Substances:

Year:  2016        PMID: 27896592     DOI: 10.1007/s11095-016-2068-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  69 in total

1.  The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties.

Authors:  B Moosmann; C Behl
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 2.  Antioxidants as treatment for neurodegenerative disorders.

Authors:  Bernd Moosmann; Christian Behl
Journal:  Expert Opin Investig Drugs       Date:  2002-10       Impact factor: 6.206

3.  Membrane protein oxidation determines neuronal degeneration.

Authors:  Parvana Hajieva; Nadhim Bayatti; Matthias Granold; Christian Behl; Bernd Moosmann
Journal:  J Neurochem       Date:  2015-02-04       Impact factor: 5.372

4.  Nrf2 target genes are induced under marginal selenium-deficiency.

Authors:  Mike Müller; Antje Banning; Regina Brigelius-Flohé; Anna Kipp
Journal:  Genes Nutr       Date:  2010-01-29       Impact factor: 5.523

Review 5.  Revisiting the polar paradox theory: a critical overview.

Authors:  Fereidoon Shahidi; Ying Zhong
Journal:  J Agric Food Chem       Date:  2011-03-04       Impact factor: 5.279

6.  Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins.

Authors:  D Triguero; J Buciak; W M Pardridge
Journal:  J Neurochem       Date:  1990-06       Impact factor: 5.372

7.  Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival.

Authors:  Sotiria Sotiriou; Suzana Gispert; Jun Cheng; Yaohui Wang; Amy Chen; Shelley Hoogstraten-Miller; Georgina F Miller; Oran Kwon; Mark Levine; Susan H Guttentag; Robert L Nussbaum
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

Review 8.  A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke.

Authors:  Sean I Savitz
Journal:  Exp Neurol       Date:  2007-03-12       Impact factor: 5.330

9.  A phenothiazine derivative reduces rat brain damage after global or focal ischemia.

Authors:  M J Yu; J R McCowan; E B Smalstig; D R Bennett; M E Roush; J A Clemens
Journal:  Stroke       Date:  1992-09       Impact factor: 7.914

10.  Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group.

Authors:  G T Vatassery; S Fahn; M A Kuskowski
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

View more
  5 in total

1.  Coconut (Cocos nucifera) Ethanolic Leaf Extract Reduces Amyloid-β (1-42) Aggregation and Paralysis Prevalence in Transgenic Caenorhabditis elegans Independently of Free Radical Scavenging and Acetylcholinesterase Inhibition.

Authors:  Rafael Vincent Manalo; Maries Ann Silvestre; Aza Lea Anne Barbosa; Paul Mark Medina
Journal:  Biomedicines       Date:  2017-04-21

Review 2.  Neuroprotection through flavonoid: Enhancement of the glyoxalase pathway.

Authors:  Joel R Frandsen; Prabagaran Narayanasamy
Journal:  Redox Biol       Date:  2017-10-18       Impact factor: 11.799

Review 3.  Neuroprotective Natural Molecules, From Food to Brain.

Authors:  Joaquin González-Fuentes; Jorge Selva; Carmen Moya; Lucia Castro-Vázquez; Maria V Lozano; Pilar Marcos; Maria Plaza-Oliver; Virginia Rodríguez-Robledo; Manuel J Santander-Ortega; Noemi Villaseca-González; Maria M Arroyo-Jimenez
Journal:  Front Neurosci       Date:  2018-10-23       Impact factor: 4.677

4.  N10 -carbonyl-substituted phenothiazines inhibiting lipid peroxidation and associated nitric oxide consumption powerfully protect brain tissue against oxidative stress.

Authors:  Robert G Keynes; Anastasia Karchevskaya; Dieter Riddall; Charmaine H Griffiths; Tomas C Bellamy; A W Edith Chan; David L Selwood; John Garthwaite
Journal:  Chem Biol Drug Des       Date:  2019-06-12       Impact factor: 2.817

Review 5.  Therapeutic Applications of Cysteamine and Cystamine in Neurodegenerative and Neuropsychiatric Diseases.

Authors:  Bindu D Paul; Solomon H Snyder
Journal:  Front Neurol       Date:  2019-12-12       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.